GLUCOPYRANOSIDE COMPOUND
    1.
    发明申请
    GLUCOPYRANOSIDE COMPOUND 有权
    葡萄糖苷化合物

    公开(公告)号:US20120058941A1

    公开(公告)日:2012-03-08

    申请号:US13174814

    申请日:2011-07-01

    摘要: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译: 下式的化合物:其中环A和环B是:(1)环A是任选取代的不饱和单环杂环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环,或 任选取代的苯环,(2)环A是任选取代的苯环,环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环,或(3)环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y为 - (CH 2)n - (n为1或2); 或其药学上可接受的盐,或其前药。

    Glucopyranoside compound
    2.
    发明授权
    Glucopyranoside compound 有权
    吡喃葡萄糖苷化合物

    公开(公告)号:US07943788B2

    公开(公告)日:2011-05-17

    申请号:US11045446

    申请日:2005-01-31

    摘要: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译: 下式的化合物:其中环A和环B是:(1)环A是任选取代的不饱和单环杂环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环,或 任选取代的苯环,(2)环A是任选取代的苯环,环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环,或(3)环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y为 - (CH 2)n - (n为1或2); 其药学上可接受的盐或其前药。

    Novel compounds
    3.
    发明申请
    Novel compounds 有权
    新型化合物

    公开(公告)号:US20050233988A1

    公开(公告)日:2005-10-20

    申请号:US11045446

    申请日:2005-01-31

    摘要: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译: 下式的化合物:其中环A和环B是:(1)环A是任选取代的不饱和单环杂环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环,或 任选取代的苯环,(2)环A是任选取代的苯环,环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环,或(3)环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y是 - (CH 2)n - (n是1或2); 其药学上可接受的盐或其前药。

    GLUCOPYRANOSIDE COMPOUND
    4.
    发明申请
    GLUCOPYRANOSIDE COMPOUND 有权
    葡萄糖苷化合物

    公开(公告)号:US20110105424A1

    公开(公告)日:2011-05-05

    申请号:US13005757

    申请日:2011-01-13

    摘要: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译: 下式的化合物:其中环A和环B是:(1)环A是任选取代的不饱和单环杂环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环,或 任选取代的苯环,(2)环A是任选取代的苯环,环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环,或(3)环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y为 - (CH 2)n - (n为1或2); 或其药学上可接受的盐,或其前药。

    Glucopyranoside compound
    5.
    发明授权
    Glucopyranoside compound 有权
    吡喃葡萄糖苷化合物

    公开(公告)号:US08785403B2

    公开(公告)日:2014-07-22

    申请号:US13494602

    申请日:2012-06-12

    IPC分类号: C07H5/02 A01N43/04 A61K31/70

    摘要: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译: 下式的化合物:其中环A和环B是:(1)环A是任选取代的不饱和单环杂环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环,或 任选取代的苯环,(2)环A是任选取代的苯环,环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环,或(3)环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y为 - (CH 2)n - (n为1或2); 或其药学上可接受的盐,或其前药。

    Glucopyranoside compound
    6.
    发明授权

    公开(公告)号:US08222219B2

    公开(公告)日:2012-07-17

    申请号:US13174814

    申请日:2011-07-01

    IPC分类号: A01N43/04 A61K31/70

    摘要: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    Glucopyranoside compound
    7.
    发明授权
    Glucopyranoside compound 有权
    吡喃葡萄糖苷化合物

    公开(公告)号:US08202984B2

    公开(公告)日:2012-06-19

    申请号:US13005757

    申请日:2011-01-13

    摘要: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译: 下式的化合物:其中环A和环B是:(1)环A是任选取代的不饱和单环杂环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环,或 任选取代的苯环,(2)环A是任选取代的苯环,环B是任选取代的不饱和单环杂环或任选取代的不饱和稠环杂双环,或(3)环A是任选取代的不饱和稠合杂双环 环和环B独立地是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的苯环; X是碳原子或氮原子; Y为 - (CH 2)n - (n为1或2); 或其药学上可接受的盐,或其前药。

    N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter
    8.
    发明授权
    N-glucoside compounds having an inhibitory activity against sodium-dependent glucose transporter 失效
    对钠依赖性葡萄糖转运蛋白具有抑制活性的N-葡萄糖苷化合物

    公开(公告)号:US07521430B2

    公开(公告)日:2009-04-21

    申请号:US10566585

    申请日:2004-07-30

    CPC分类号: C07H15/203 C07H5/04 C07H17/02

    摘要: A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH2— group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译: 下式的化合物:其中环A和环B是(1)环A是任选取代的不饱和单环杂环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选地 取代的苯环,(2)环A是任选取代的苯环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的苯环,或(3)环A是 任选取代的不饱和稠合杂双环,其中-NR-基和-CH2-基都在不饱和稠合杂双环的相同环上,环B是任选取代的单环不饱和杂环,任选取代的不饱和稠合杂双环 ,或任选取代的苯环; 或其前体药物,R为氢原子,低级烷基,低级烷酰基或低级烷氧基羰基,或其药学上可接受的盐。

    Novel compounds
    9.
    发明申请
    Novel compounds 失效
    新型化合物

    公开(公告)号:US20070060545A1

    公开(公告)日:2007-03-15

    申请号:US10566585

    申请日:2004-07-30

    IPC分类号: A61K31/7008 C07H5/04

    CPC分类号: C07H15/203 C07H5/04 C07H17/02

    摘要: A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH2— group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

    摘要翻译: 下式的化合物:其中环A和环B是(1)环A是任选取代的不饱和单环杂环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的不饱和单环杂环 取代的苯环,(2)环A是任选取代的苯环,环B是任选取代的不饱和单环杂环,任选取代的不饱和稠合杂双环或任选取代的苯环,或(3)环A是 任选取代的不饱和稠合杂双环,其中-NR-基团和-CH 2 - 基团都在不饱和稠合杂双环环的相同环上,环B是任选取代的单环不饱和杂环 ,任选取代的不饱和稠合杂双环,或任选取代的苯环; 或其前体药物,R为氢原子,低级烷基,低级烷酰基或低级烷氧基羰基,或其药学上可接受的盐。